Pfizer Inc.
Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
Last updated:
Abstract:
Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
24 Jun 2019
Issue date:
27 Oct 2020